¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2025-2032³â)
Catheter Associated Urinary Tract Infections Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Áö¼Ó¼º ½ÃÀå Á¶»ç´Â ÃÖ±Ù ¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°(CAUTI) Ä¡·á ½ÃÀå¿¡ ´ëÇÑ Æ÷°ýÀûÀÎ º¸°í¼¸¦ ¹ßÇ¥Çϰí ÃßÁø ¿äÀÎ, ½ÅÈï µ¿Çâ, ±âȸ ¹× °úÁ¦¸¦ Æ÷ÇÔÇÑ ÁÖ¿ä ½ÃÀå ¿ªÇп¡ ´ëÇÑ ½ÉÃþ ºÐ¼®À» Á¦°øÇß½À´Ï´Ù. ÀÌ º¸°í¼´Â ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀÌÇØ¸¦ Á¦°øÇÏ¿© ÀÌÇØ°ü°èÀÚ°¡ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå ±Ô¸ð(2025³â) : 15¾ï ´Þ·¯
½ÃÀå ±Ô¸ð ¿¹Ãø(±Ý¾× ±âÁØ, 2032³â) : 19¾ï ´Þ·¯
¼¼°è ½ÃÀåÀÇ ¼ºÀå·ü(CAGR, 2025-2032³â) : 3.70%
Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿° Ä¡·á ½ÃÀå : ºÐ¼® ¹üÀ§
¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°(CAUTI) Ä¡·á ½ÃÀåÀº ¿ä·Î Ä«Å×ÅÍ »ç¿ëÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â °¨¿°À» °ü¸®ÇÏ°í ±ÙÀýÇϱâ À§ÇØ °í¾ÈµÈ Ä¡·á °³ÀÔ¿¡ ÁßÁ¡À» µÓ´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°Àº ÀÇ·á ȯ°æ, ƯÈ÷ À¯Ä¡ Ä«Å×Å͸¦ »ç¿ëÇϴ ȯÀÚµé »çÀÌ¿¡¼ ³Î¸® ÆÛÁø ÇÕº´ÁõÀÔ´Ï´Ù. Ä¡·áÀÇ ÁÖ¿ä ¸ñÇ¥´Â ¹ÚÅ׸®¾Æ °¨¿°À» ÅðÄ¡ÇÏ°í º´¿ø±ÕÀÇ È®»êÀ» ¹æÁöÇϸç Àü½Å ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÌ´Â °ÍÀÔ´Ï´Ù. Ä¡·á ¿É¼Ç¿¡´Â ÀϹÝÀûÀ¸·Î Ç×±ÕÁ¦°¡ Æ÷ÇÔµÇÁö¸¸, Ç×»ýÁ¦ ³»¼º¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö¸é¼ Çõ½ÅÀûÀÎ Ä¡·á¹ý°ú Ç×±Õ ±â¼ú¿¡ ´ëÇÑ ¿¬±¸°¡ Ȱ¹ßÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¿ä·Î Ä«Å×ÅÍÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀ¸·Î ÀÎÇØ CAUTIÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
Ä«Å×ÅÍ °ü·Ã °¨¿°¿¡ ´õ Ãë¾àÇÑ Àü ¼¼°è Àα¸ÀÇ °í·ÉÈ·Î ÀÎÇØ CAUTI Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀÌ Å©°Ô °ßÀεǰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² Çõ½ÅÀûÀÎ Ç×»ýÁ¦, ¼Òµ¶Á¦, °¨¿° ÀúÇ×¼ºÀÌ ³»ÀåµÈ Ä«Å×ÅÍ Àç·áÀÇ °³¹ßÀ» ºñ·ÔÇÑ Ä¡·á ¹æ½ÄÀÇ ¹ßÀüÀº CAUTI °ü¸®¸¦ °³¼±ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ƯÈ÷ Ç×»ýÁ¦ ³»¼ºÀ¸·Î ÀÎÇØ ±âÁ¸ÀÇ Ç×»ýÁ¦ ¿ä¹ýÀÌ ÃæºÐÇÏÁö ¾ÊÀ» ¼ö ÀÖ´Â °æ¿ì¿¡ º¸´Ù Ç¥Àûȵǰí È¿°úÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Ä«Å×ÅÍ¿¡ Ç×±Õ ÄÚÆÃ°ú Ç¥Àû ¾à¹° Àü´Þ ½Ã½ºÅÛ°ú °°Àº ÷´Ü ±â¼úÀÇ ÅëÇÕÀ¸·Î °¨¿° ¿¹¹æ ¹× Ä¡·á È¿°ú°¡ Çâ»óµÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ±âÁ¸ÀÇ Ä¡·á °ÝÂ÷¸¦ ÇØ¼ÒÇÒ »Ó¸¸ ¾Æ´Ï¶ó °¨¿° ÀüÆÄÀÇ À§ÇèÀ» ÁÙ¿© ´õ ³ªÀº ȯÀÚ Ä¡·á °á°ú¿¡ ±â¿©ÇÕ´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
À¯¸ÁÇÑ ¼ºÀå¼¼¿¡µµ ºÒ±¸ÇÏ°í ½ÃÀåÀº »ó´çÇÑ µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ½Å¾à ¹× ÀÇ·á ±â±â¿¡ ´ëÇÑ ¾ö°ÝÇÑ ½ÂÀÎ ÀýÂ÷¸¦ Æ÷ÇÔÇÑ ±ÔÁ¦ Àå¾Ö¹°Àº Á¦Ç° Ãâ½Ã¸¦ Áö¿¬½ÃÄÑ ½ÃÀå ¹ßÀüÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ¿ä±¸¸¦ ÃæÁ·ÇÒ ¼ö ÀÖ´Â ÀÚ¿øÀ» °®Ãá ´ëÇü Á¦¾à ¹× ÀÇ·á ±â±â ȸ»ç°¡ ½ÃÀåÀ» Áö¹èÇÒ °¡´É¼ºÀÌ ³ôÀ¸¸ç, ÀÌ´Â ¼Ò±Ô¸ð ±â¾÷ÀÇ ±âȸ¸¦ Á¦ÇÑÇÏ°í ½ÃÀåÀÇ ´Ù¾ç¼ºÀ» °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç×»ýÁ¦ ³»¼º ¹®Á¦°¡ ±¤¹üÀ§ÇÏ°Ô ÆÛÁ® ÀÖ´Â °Íµµ CAUTI Ä¡·á ȯ°æÀÇ ÁÖ¿ä Àå¾Ö¹°·Î ³²¾Æ ÀÖ½À´Ï´Ù. ±âÁ¸ Ç×»ýÁ¦¿¡ ´ëÇÑ ¹ÚÅ׸®¾Æ ±ÕÁÖÀÇ ³»¼ºÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼º°øÀûÀÎ Ä¡·á °á°ú¸¦ ´Þ¼ºÇϱⰡ Á¡Á¡ ´õ ¾î·Á¿öÁö°í ÀÖÀ¸¸ç, »õ·Î¿î Ç×±ÕÁ¦¿Í ´ëü Ä¡·á Á¢±Ù¹ýÀÇ °³¹ßÀÌ ÇÊ¿äÇØÁ³½À´Ï´Ù.
½ÃÀå ±âȸ
CAUTI Ä¡·á ½ÃÀåÀº ƯÈ÷ »õ·Î¿î Ä¡·á¹ý°ú ±â¼ú °³¹ßÀ» ÅëÇØ »ó´çÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. °¨¿° À§ÇèÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ´Â Ä«Å×ÅÍ¿ë Ç×±Õ ÄÚÆÃÀÇ Ã¤Åà °¡´É¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »õ·Î¿î ¾à¹° Á¦Çü°ú ÷´Ü ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ »ç¿ëÀº È¿°úÀûÀÎ Ä¡·á¸¦ À§ÇÑ »õ·Î¿î ±æÀ» Á¦½ÃÇÕ´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°øÀÚ°¡ °¨¿° ¿¹¹æ ¹× °ü¸®¸¦ ¿ì¼±½ÃÇÔ¿¡ µû¶ó ÀÇ·á ±â¼úÀÇ Çõ½Å°ú ÇÔ²² ¿¬±¸ °³¹ß ÀÌ´Ï¼ÅÆ¼ºê°¡ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÅõÀÚ Áõ°¡¿Í °¨¿° °ü¸® ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ½ÃÀåÀº CAUTIÀÇ º¹À⼺À» ÇØ°áÇϰí ȯÀÚ Ä¡·á¸¦ °³¼±Çϴ ÷´Ü Ä¡·á¹ýÀ» µµÀÔÇÒ ¼ö ÀÖ´Â »õ·Î¿î ±âȸ¸¦ âÃâÇÒ °ÍÀÔ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´äº¯À» ¾òÀ» ¼ö ÀÖ´Â ÁÖ¿ä Áú¹®
Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
CAUTI Ä¡·á ½ÃÀå¿¡¼ ¾î¶² »õ·Î¿î ±â¼ú°ú Ä¡·á ¹æ¹ýÀÌ ÁÖ¸ñÀ» ¹Þ°í Àִ°¡?
¿¹Ãø±â°£ Áß °¡Àå ³ôÀº ½ÃÀå ¼ºÀåÀÌ ¿¹»óµÇ´Â Áö¿ªÀº?
Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº? ¶ÇÇÑ ¾î¶² Àü·«À¸·Î ±× ÁöÀ§¸¦ À¯ÁöÇϰí Àִ°¡?
ÀÇ·á ±â¼úÀÇ Áøº¸´Â ½ÃÀå °æÀï ±¸µµ¸¦ ¾î¶»°Ô Çü¼ºÇϴ°¡?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
¶óÀÌÇÁ»çÀÌŬ ºÐ¼® : ¾àÁ¦À¯Çüº°
Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå : ¹ë·ùüÀÎ
¿øÀç·á °ø±Þ¾÷ü ¸ñ·Ï
Á¦Á¶¾÷ü À϶÷
¸®¼¿·¯ À϶÷
À¯Åë ä³Î À϶÷
¼öÀͼº ºÐ¼®
Æ÷ÅÍ Five ForcesÀÇ ºÐ¼®
ÁöÁ¤ÇÐÀû ±äÀå : ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ¼½Åͺ° Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
¼¼°èÀÇ »óÀ§ ½ÃÀå °³¿ä
¿¹Ãø ¿äÀÎ : °ü·Ã¼º°ú ¿µÇâ
¿¹Ãø ¿äÀÎ : °ü·Ã¼º°ú ¿µÇâ
±ÔÁ¦¿Í ±â¼úÀÇ »óȲ
Á¦3Àå ¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2025-2032³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð ¿¹Ãø(¼ö·® ±âÁØ)
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
Àý´ë ¼öÀÍ ±âȸ
½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ)
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®(2019-2023³â)
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø(2025-2032³â)
¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : ¾àÁ¦À¯Çüº°
¼Ò°³ ¹× ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ¾àÁ¦À¯Çüº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2019-2023³â)
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø : ¾àÁ¦ À¯Çüº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2025-2032³â)
Æä´Ï½Ç¸°°ú ±× Á¶ÇÕ
Äû³î·Ð
¼¼ÆÈ·Î½ºÆ÷¸°
¾Æ¹Ì³ë±Û¸®Äڽõå°è Ç×»ýÁ¦
¼úÆù¾Æ¹Ìµå
¾ÆÁ¹°ú ¾ÏÆ÷Å׸®½Å B
Åׯ®¶ó »çÀÌŬ¸°
´ÏÆ®·ÎǪ¶õ
±âŸ
½ÃÀå ¸Å·Â ºÐ¼® : ¾àÁ¦À¯Çüº°
¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : ÀûÀÀÁõÀ¯Çüº°
¼Ò°³ ¹× ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ÀûÀÀÁõÀ¯Çüº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2019-2023³â)
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø : ÀûÀÀÁõÀ¯Çüº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2025-2032³â)
¹«Áõ»ó¼º CAUTI(¼¼±Õ´¢)
ÁõÈļº CAUTI(±ÕÇ÷Áõ)
½ÃÀå ¸Å·Â ºÐ¼® : ÀûÀÀÁõÀ¯Çüº°
¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : À¯Åë ä³Îº°
¼Ò°³ ¹× ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : À¯Åëä³Îº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2019-2023³â)
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø : À¯Åëä³Îº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2025-2032³â)
º´¿ø ¾à±¹
ºÎÀΰú, ºñ´¢±â°ú Ŭ¸®´Ð
¾à±¹
¼Ò¸Å ¾à±¹
¿Â¶óÀÎ ¾à±¹
½ÃÀå ¸Å·Â ºÐ¼® : À¯Åë ä³Îº°
Á¦4Àå ¼¼°èÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : Áö¿ªº°
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Áö¿ªº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2019-2023³â)
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø : Áö¿ªº°(±Ý¾×(10¾ï ´Þ·¯), ¼ö·® ±âÁØ, 2025-2032³â)
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ, ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦5Àå ºÏ¹ÌÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2025-2032³â)
Á¦6Àå À¯·´ÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2025-2032³â)
Á¦7Àå µ¿¾Æ½Ã¾ÆÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2025-2032³â)
Á¦8Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2025-2032³â)
Á¦9Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2025-2032³â)
Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°Áõ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2025-2032³â)
Á¦11Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®(2025³â)
½ÃÀå ±¸Á¶
°æÀï °µµ ¸ÅÇÎ : ½ÃÀ庰
°æÀï : Äû³î·Ð
°Ñº¸±â Á¦Ç° ¿ë·®
±â¾÷ ÇÁ·ÎÆÄÀÏ(»ó¼¼ : °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
Pfizer Inc.
Merck &Co., Inc.
GlaxoSmithKline(GSK)
AstraZeneca
Bayer AG
Johnson &Johnson
Novartis International AG
Sanofi
Roche Holding AG
Eli Lilly and Company
Bristol-Myers Squibb Company
Abbott Laboratories
Astellas Pharma Inc.
Boehringer Ingelheim
Daiichi Sankyo Company, Limited
Gilead Sciences, Inc.
Mylan NV
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Á¦12Àå ºÎ·Ï
ºÐ¼® ¹æ¹ý
ºÐ¼®ÀÇ ÀüÁ¦Á¶°Ç
µÎÀÚ¾î ¹× ¾à¾î
HBR
Persistence Market Research has recently released a comprehensive report on the global Catheter Associated Urinary Tract Infections (CAUTI) Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.
Key Insights:
Catheter Associated Urinary Tract Infections Treatment Market Size (2025E): US$1.5 Bn
Projected Market Value (2032F): US$1.9 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 3.70%
Catheter Associated Urinary Tract Infections Treatment Market - Report Scope:
The global catheter associated urinary tract infections (CAUTIs) treatment market focuses on therapeutic interventions designed to manage and eradicate infections that arise from the use of urinary catheters. These infections are prevalent complications in healthcare settings, particularly among patients with indwelling catheters. The primary aim of treatment is to combat bacterial infections, prevent the spread of pathogens, and reduce the risk of systemic complications. Treatment options typically include antimicrobial agents, although growing concerns about antibiotic resistance have driven research into innovative therapies and antimicrobial technologies. The increasing incidence of CAUTIs, amplified by the widespread use of urinary catheters, further propels the demand for effective treatment solutions.
Market Drivers:
The growth of the CAUTI treatment market is being significantly driven by the aging global population, which is more prone to catheter-associated infections. In parallel, advancements in treatment modalities, including the development of innovative antibiotics, antiseptics, and catheter materials with built-in infection-resistant properties, are crucial in enhancing CAUTI management. These advancements allow for more targeted and effective treatments, particularly in cases where traditional antibiotic therapies may not be sufficient due to antibiotic resistance. The integration of cutting-edge technologies, such as antibacterial coatings on catheters and targeted drug delivery systems, has improved infection prevention and treatment efficacy, further driving market growth. These innovations not only address the existing treatment gap but also reduce the risk of infection transmission, contributing to better patient outcomes.
Market Restraints:
Despite the promising growth, the market faces significant challenges. Regulatory hurdles, including the stringent approval processes for new medications and medical devices, could delay product introductions, thereby hindering market progress. Larger pharmaceutical and medical device companies, with the resources to meet these regulatory demands, are likely to dominate the market, which could limit opportunities for smaller companies and reduce market diversity. Additionally, the widespread issue of antibiotic resistance remains a major obstacle in the CAUTI treatment landscape. The increasing resistance of bacterial strains to conventional antibiotics makes it increasingly difficult to achieve successful treatment outcomes, necessitating the development of new antimicrobial agents and alternative treatment approaches.
Market Opportunities:
The CAUTI treatment market presents significant growth opportunities, particularly through the development of novel therapies and technologies. There is increasing potential in the adoption of antimicrobial coatings for catheters, which can significantly reduce the risk of infections. Furthermore, novel drug formulations and the use of advanced drug delivery systems offer new avenues for effective treatment. As healthcare providers prioritize infection prevention and management, research and development initiatives, along with innovations in medical technology, are expected to expand. The market is also poised to benefit from increased healthcare investments and advancements in infection control technologies, creating new opportunities for the introduction of advanced treatments that address the complexities of CAUTIs and improve patient care.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the catheter associated urinary tract infections treatment market?
What novel technologies and treatment modalities are gaining traction in the CAUTI treatment market?
Which regions are expected to experience the highest market growth over the forecast period?
Who are the key players in the catheter associated urinary tract infections treatment market, and what strategies are they using to maintain their positions?
How are advancements in healthcare technologies shaping the competitive landscape of the market?
Competitive Intelligence and Business Strategy:
Leading players in the global CAUTI treatment market are focusing on product innovation, clinical trials, and collaborations with research institutions to maintain a competitive edge. These companies are investing heavily in developing advanced antimicrobial technologies, such as catheter coatings and drug delivery systems, to address the growing challenges of CAUTI management. Additionally, strategic partnerships with healthcare providers and academic institutions are accelerating the development of new solutions to improve patient outcomes and reduce healthcare-associated infections. Companies are also exploring opportunities to expand their portfolios to include a broader range of treatment options that address the complexities associated with CAUTIs, ensuring they meet the diverse needs of the global healthcare market.
Key Companies Profiled:
Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline (GSK)
AstraZeneca
Bayer AG
Johnson & Johnson
Novartis International AG
Sanofi
Roche Holding AG
Eli Lilly and Company
Bristol-Myers Squibb Company
Abbott Laboratories
Astellas Pharma Inc.
Boehringer Ingelheim
Daiichi Sankyo Company, Limited
Gilead Sciences, Inc.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Catheter Associated Urinary Tract Infections Treatment Market Segmentation:
By Drug Type:
Penicillin & Combinations
Quinolones
Cephalosporin
Aminoglycoside Antibiotics
Sulphonamides (Sulfamethoxazole +Trimethoprim)
Azoles and Amphotericin B
Tetracycline (Doxycycline)
Nitrofura
By Indication Type:
Asymptomatic CAUTI (Bacteriuria)
Symptomatic CAUTI (Bacteremic)
By Distribution Channel:
Hospital Pharmacies
Gynaecology and Urology Clinics
Drug Stores
Retail Pharmacies
Online Drug Stores
By Region:
North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Catheter-Associated Urinary Tract Infections Treatment Market Snapshot, 2025 - 2032
1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Type Lifecycle Analysis
2.4. Catheter-Associated Urinary Tract Infections Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Distribution Channels
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Bn ) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2019 - 2023
3.2.2. Current Market Size Forecast, 2025 - 2032
3.3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Drug Type
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Drug Type, 2019 - 2023
3.3.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
3.3.3.1. Penicillin & Combinations
3.3.3.2. Quinolones
3.3.3.3. Cephalosporin
3.3.3.4. Aminoglycoside Antibiotics
3.3.3.5. Sulphonamides
3.3.3.6. Azoles and Amphotericin B
3.3.3.7. Tetracycline
3.3.3.8. Nitrofurans
3.3.3.9. Other
3.4. Market Attractiveness Analysis: Drug Type
3.5. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Indication Type
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Indication Type, 2019 - 2023
3.5.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
3.5.3.1. Asymptomatic CAUTI (Bacteriuria)
3.5.3.2. Symptomatic CAUTI (Bacteremic)
3.6. Market Attractiveness Analysis: Indication Type
3.7. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Distribution Channel
3.7.1. Introduction / Key Findings
3.7.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Distribution Channel, 2019 - 2023
3.7.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
3.7.3.1. Hospital Pharmacies
3.7.3.2. Gynaecology and Urology Clinics
3.7.3.3. Drug Stores
3.7.3.4. Retail Pharmacies
3.7.3.5. Online Drug Stores
3.8. Market Attractiveness Analysis: Distribution Channel
4. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Region, 2019 - 2023
4.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Region, 2025 - 2032
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia & Pacific
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
5.3.1. By Country
5.3.2. By Drug Type
5.3.3. By Indication Type
5.3.4. By Distribution Channel
5.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
5.5.1. Penicillin & Combinations
5.5.2. Quinolones
5.5.3. Cephalosporin
5.5.4. Aminoglycoside Antibiotics
5.5.5. Sulphonamides
5.5.6. Azoles and Amphotericin B
5.5.7. Tetracycline
5.5.8. Nitrofurans
5.5.9. Other
5.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
5.6.1. Asymptomatic CAUTI (Bacteriuria)
5.6.2. Symptomatic CAUTI (Bacteremic)
5.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
5.7.1. Hospital Pharmacies
5.7.2. Gynaecology and Urology Clinics
5.7.3. Drug Stores
5.7.4. Retail Pharmacies
5.7.5. Online Drug Stores
5.8. Market Attractiveness Analysis
6. Europe Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
6.3.1. By Country
6.3.2. By Drug Type
6.3.3. By Indication Type
6.3.4. By Distribution Channel
6.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Turkey
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
6.5.1. Penicillin & Combinations
6.5.2. Quinolones
6.5.3. Cephalosporin
6.5.4. Aminoglycoside Antibiotics
6.5.5. Sulphonamides
6.5.6. Azoles and Amphotericin B
6.5.7. Tetracycline
6.5.8. Nitrofurans
6.5.9. Other
6.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
6.6.1. Asymptomatic CAUTI (Bacteriuria)
6.6.2. Symptomatic CAUTI (Bacteremic)
6.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
6.7.1. Hospital Pharmacies
6.7.2. Gynaecology and Urology Clinics
6.7.3. Drug Stores
6.7.4. Retail Pharmacies
6.7.5. Online Drug Stores
6.8. Market Attractiveness Analysis
7. East Asia Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
7.3.1. By Country
7.3.2. By Drug Type
7.3.3. By Indication Type
7.3.4. By Distribution Channel
7.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
7.5.1. Penicillin & Combinations
7.5.2. Quinolones
7.5.3. Cephalosporin
7.5.4. Aminoglycoside Antibiotics
7.5.5. Sulphonamides
7.5.6. Azoles and Amphotericin B
7.5.7. Tetracycline
7.5.8. Nitrofurans
7.5.9. Other
7.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
7.6.1. Asymptomatic CAUTI (Bacteriuria)
7.6.2. Symptomatic CAUTI (Bacteremic)
7.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
7.7.1. Hospital Pharmacies
7.7.2. Gynaecology and Urology Clinics
7.7.3. Drug Stores
7.7.4. Retail Pharmacies
7.7.5. Online Drug Stores
7.8. Market Attractiveness Analysis
8. South Asia & Pacific Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
8.3.1. By Country
8.3.2. By Drug Type
8.3.3. By Indication Type
8.3.4. By Distribution Channel
8.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Pacific
8.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
8.5.1. Penicillin & Combinations
8.5.2. Quinolones
8.5.3. Cephalosporin
8.5.4. Aminoglycoside Antibiotics
8.5.5. Sulphonamides
8.5.6. Azoles and Amphotericin B
8.5.7. Tetracycline
8.5.8. Nitrofurans
8.5.9. Other
8.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
8.6.1. Asymptomatic CAUTI (Bacteriuria)
8.6.2. Symptomatic CAUTI (Bacteremic)
8.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
8.7.1. Hospital Pharmacies
8.7.2. Gynaecology and Urology Clinics
8.7.3. Drug Stores
8.7.4. Retail Pharmacies
8.7.5. Online Drug Stores
8.8. Market Attractiveness Analysis
9. Latin America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Indication Type
9.3.4. By Distribution Channel
9.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
9.5.1. Penicillin & Combinations
9.5.2. Quinolones
9.5.3. Cephalosporin
9.5.4. Aminoglycoside Antibiotics
9.5.5. Sulphonamides
9.5.6. Azoles and Amphotericin B
9.5.7. Tetracycline
9.5.8. Nitrofurans
9.5.9. Other
9.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
9.6.1. Asymptomatic CAUTI (Bacteriuria)
9.6.2. Symptomatic CAUTI (Bacteremic)
9.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
9.7.1. Hospital Pharmacies
9.7.2. Gynaecology and Urology Clinics
9.7.3. Drug Stores
9.7.4. Retail Pharmacies
9.7.5. Online Drug Stores
9.8. Market Attractiveness Analysis
10. Middle East & Africa Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Indication Type
10.3.4. By Distribution Channel
10.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
10.5.1. Penicillin & Combinations
10.5.2. Quinolones
10.5.3. Cephalosporin
10.5.4. Aminoglycoside Antibiotics
10.5.5. Sulphonamides
10.5.6. Azoles and Amphotericin B
10.5.7. Tetracycline
10.5.8. Nitrofurans
10.5.9. Other
10.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
10.6.1. Asymptomatic CAUTI (Bacteriuria)
10.6.2. Symptomatic CAUTI (Bacteremic)
10.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
10.7.1. Hospital Pharmacies
10.7.2. Gynaecology and Urology Clinics
10.7.3. Drug Stores
10.7.4. Retail Pharmacies
10.7.5. Online Drug Stores
10.8. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2025
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Quinolones
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Pfizer Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Merck & Co., Inc.
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. GlaxoSmithKline (GSK)
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. AstraZeneca
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Bayer AG
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Johnson & Johnson
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Novartis International AG
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Sanofi
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Roche Holding AG
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Eli Lilly and Company
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Bristol-Myers Squibb Company
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Abbott Laboratories
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
11.3.13. Astellas Pharma Inc.
11.3.13.1. Overview
11.3.13.2. Segments and Product
11.3.13.3. Key Financials
11.3.13.4. Market Developments
11.3.13.5. Market Strategy
11.3.14. Boehringer Ingelheim
11.3.14.1. Overview
11.3.14.2. Segments and Product
11.3.14.3. Key Financials
11.3.14.4. Market Developments
11.3.14.5. Market Strategy
11.3.15. Daiichi Sankyo Company, Limited
11.3.15.1. Overview
11.3.15.2. Segments and Product
11.3.15.3. Key Financials
11.3.15.4. Market Developments
11.3.15.5. Market Strategy
11.3.16. Gilead Sciences, Inc.
11.3.16.1. Overview
11.3.16.2. Segments and Product
11.3.16.3. Key Financials
11.3.16.4. Market Developments
11.3.16.5. Market Strategy
11.3.17. Mylan N.V.
11.3.17.1. Overview
11.3.17.2. Segments and Product
11.3.17.3. Key Financials
11.3.17.4. Market Developments
11.3.17.5. Market Strategy
11.3.18. Teva Pharmaceutical Industries Ltd.
11.3.18.1. Overview
11.3.18.2. Segments and Product
11.3.18.3. Key Financials
11.3.18.4. Market Developments
11.3.18.5. Market Strategy
11.3.19. Sun Pharmaceutical Industries Ltd.
11.3.19.1. Overview
11.3.19.2. Segments and Product
11.3.19.3. Key Financials
11.3.19.4. Market Developments
11.3.19.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations